Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)

REFERENCES

• Jemal A., Tiwari R. C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E. J., Thun M. J. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29
   PubMed Web of Science ®Google Scholar
• Cannistra S. A. Cancer of the ovary. N Engl J Med 2004; 351: 2519–2529
   PubMed Web of Science ®Google Scholar
• Schuijer M., Berns E. M. TP53 and ovarian cancer. Hum Mutat 2003; 21: 285–291
   PubMed Web of Science ®Google Scholar
• Manic S., Gatti L., Carenini N., Fumagalli G., Zunino F., Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003; 3: 21–29
   PubMed Web of Science ®Google Scholar
• Brabec V., Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 2005; 8: 131–146
   PubMed Web of Science ®Google Scholar
• Jones P. A., Laird P. W. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163–167
   PubMed Web of Science ®Google Scholar
• Herman J. G., Merlo A., Mao L. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar
• Sakai T., Toguchid J., Ohtani N., Yandell D. W., Rapaport J. M., Dryja T. P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48: 880–888
   PubMed Web of Science ®Google Scholar
• Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870–6875
   PubMed Web of Science ®Google Scholar
• Fleisher A. S., Esteller M., Tamura G., Rashid A., Stine O. C., Yin J., Zou T. T., Abraham J. M., Kong D., Nishizuka S., James S. P., Wilson K. T., Herman J. G., Meltzer S. J. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001; 20: 329–335
   PubMed Web of Science ®Google Scholar
• Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997; 57: 3347–3350
   PubMed Web of Science ®Google Scholar
• Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R. D., Howell S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881–4886
   PubMed Web of Science ®Google Scholar
• McCluskey L. L., Chen C., Delgadillo E., Felix J. C., Muderspach L. I., Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999; 72: 87–92
   PubMed Web of Science ®Google Scholar
• Yoon J. H., Dammann R., Pfeifer G. P. Hypermethylation of the CpG Island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001; 94: 212–217
   PubMed Web of Science ®Google Scholar
• Chiang J. W., Karlan B. Y., Cass L., Baldwin R. L. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006; 101: 403–410
   PubMed Web of Science ®Google Scholar
• Strathdee G., MacKean M. J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335–2341
   PubMed Web of Science ®Google Scholar
• Strathdee G., Appleton K., Illand M., Millan D. W., Sargent J., Paul J., Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158: 1121–1127
   PubMed Web of Science ®Google Scholar
• Teodoridis J. M., Hall J., Marsh S., Kannall H. D., Smyth C., Curto J., Siddiqui N., Gabra H., McLeod H. L., Strathdee G., Brown R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65: 8961–8967
   PubMed Web of Science ®Google Scholar
• Liu J. R., Opipari A. W., Tan L., Jiang Y., Zhang Y., Tang H., Nunez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62: 924–931
   PubMed Web of Science ®Google Scholar
• Anthoney D. A., McIlwrath A. J., Gallagher W. M., Edlin A. R.M., Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug resistant tumor cells. Cancer Res 1996; 56: 1374–1381
   PubMed Web of Science ®Google Scholar
• Benedet J. L., Bender H., Jones H., III, Ngan H. Y., Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209–262
   PubMed Web of Science ®Google Scholar
• Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–9826
   PubMed Web of Science ®Google Scholar
• Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003; 90: S39–44
   PubMed Web of Science ®Google Scholar
• Maruyama R., Toyooka S., Toyooka K. O., Harada K., Virmani A. K., Zochbauer-Muller S., Farinas A. J., Vakar-Lopez F., Minna J. D., Sagalowsky A., Czerniak B., Gazdar A. F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61: 8659–8663
   PubMed Web of Science ®Google Scholar
• Wiley A., Katsaros D., Chen H., Rigault de la Longrais I. A., Beeghly A., Puopolo M., Singal R., Zhang Y., Amoako A., Zelterman D., Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006; 107: 299–308
   PubMed Web of Science ®Google Scholar
• Makarla P. B., Saboorian M. H., Ashfaq R., Toyooka K. O., Toyooka S., Minna J. D., Gazdar A. F., Schorge J. O. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005; 11: 5365–5369
   PubMed Web of Science ®Google Scholar
• Park M. S., De Leon M., Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13: 858–865
   PubMed Web of Science ®Google Scholar
• Sedletska Y., Giraud-Panis M. J., Malinge J. M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251–265
   PubMedGoogle Scholar
• Cepeda V., Fuertes M. A., Castilla J., Alonso C., Quevedo C., Perez J. M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3–18
   PubMed Web of Science ®Google Scholar
• Scully R., Livingston D. M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408: 429–432
   PubMed Web of Science ®Google Scholar
• Thangaraju M., Kaufmann S. H., Couch F. J. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000; 275: 33487–33496
   PubMed Web of Science ®Google Scholar
• Xu X., Qiao W., Linke S. P., Cao L., Li W. M., Furth P. A., Harris C. C., Deng C. X. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001; 28: 266–271
   PubMed Web of Science ®Google Scholar
• Quinn J. E., Kennedy R. D., Mullan P. B., Gilmore P. M., Carty M., Johnston P. G., Harkin D. P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221–6228
   PubMed Web of Science ®Google Scholar
• Sgagias M. K., Wagner K. U., Hamik B., Stoeger S., Spieker R., Huber L. J., Chodosh L. A., Cowan K. H. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004; 3: 1451–1456
   PubMed Web of Science ®Google Scholar
• Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M. L., Goel A., Barbieri V., Costanzo F., Boland C. R., Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285–1291
   PubMed Web of Science ®Google Scholar
• Kennedy R. D., Quinn J. E., Mullan P. B., Johnston P. G., Harkin D. P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659–1668
   PubMed Web of Science ®Google Scholar
• Fedier A., Steiner R. A., Schwarz V. A., Lenherr L., Haller U., Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003; 22: 1169–1173
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S. V., Mathew C. G., Joenje H., Mok S. C., D'Andrea A. D. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568–574
   PubMed Web of Science ®Google Scholar
• Catteau A., Harris W. H., Xu C. F., Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18: 1957–1965
   PubMed Web of Science ®Google Scholar
• Esteller M., Silva J. M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I. C., Repasky E. A., Gabrielson E., Schutte M., Baylin S. B., Herman J. G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564–569
   PubMed Web of Science ®Google Scholar
• Esteller M., Garcia-Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B., Herman J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–1354
   PubMed Web of Science ®Google Scholar
• Gerson S. L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296–307
   PubMed Web of Science ®Google Scholar
• Brandes A. A., Tosoni A., Cavallo G., Reni M., Franceschi E., Bonaldi L., Bertorelle R., Gardiman M., Ghimenton C., Iuzzolino P., Pession A., Blatt V., Ermani M. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24: 4746–4753
   PubMed Web of Science ®Google Scholar
• Blanc J. L., Wager M., Guilhot J., Kusy S., Bataille B., Chantereau T., Lapierre F., Larsen C. J., Karayan-Tapon L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004; 68: 275–283
   PubMed Web of Science ®Google Scholar
• Brown R., Hirst G., Gallagher W. M., Mcllwrath A. J.; Van der Zee, A.; Anthoney, D.A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45–52
   Google Scholar
• Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R. D., Boland C. R., Koi M., Fishel R., Howell S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087–3090
   PubMed Web of Science ®Google Scholar
• Plumb J. A., Strathdee G., Sludden J., Kaye S. B., Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039–6044
   PubMed Web of Science ®Google Scholar
• Helleman J., van Staveren I. L., Dinjens W. N., van Kuijk P. F., Ritstier K., Ewing P. C., van der Burg M. E., Stoter G., Berns E. M. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 2006; 6: 201
   PubMed Web of Science ®Google Scholar
• Scartozzi M., De Nictolis M., Galizia E., Carassai P., Bianchi F., Berardi R., Gesuita R., Piga A., Cellerino R., Porfiri E. Loss of hMLH1 expression correlates with improved survival in stage III IV ovarian cancer patients. Eur J Cancer 2003; 39: 1144–1149
   PubMed Web of Science ®Google Scholar
• Samimi G., Fink D., Varki N. M., Husain A., Hoskins W. J., Alberts D. S., Howell S. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000; 6: 1415–1421
   PubMed Web of Science ®Google Scholar
• Auersperg N., Edelson M. I., Mok S. C., Johnson S. W., Hamilton T. C. The biology of ovarian cancer. Semin Oncol 1998; 25: 281–304
   PubMed Web of Science ®Google Scholar
• Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000; 19: 3138–3145
   PubMed Web of Science ®Google Scholar
• Katsaros D., Cho W., Singal R., Fracchioli S., Rigault De La Longrais I. A., Arisio R., Massobrio M., Smith M., Zheng W., Glass J., Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004; 94: 685–692
   PubMed Web of Science ®Google Scholar
• Esteller M., Corn P. G., Baylin S. B., Herman J. G. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–3229
   PubMed Web of Science ®Google Scholar
• Baylin S. B., Herman J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168–174
   PubMed Web of Science ®Google Scholar
• Tam K. F., Liu V. W., Liu S. S., Tsang P. C., Cheung A. N., Yip A. M., Ngan H. Y. Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 2007; 133: 331–341
   PubMed Web of Science ®Google Scholar